



Figure 1. Deviant lysosomal Ca²⁺ signalling in neurodegeneration. Schematic relating dysfunction of Ca²⁺-permeable channels in lysosomes (inner perimeter) to neurodegenerative disease (outer perimeter).

both are Ca²⁺-permeable (LaPlante et al., 2002; Schieder et al., 2010). It is however interesting that the ion selectivity of these channels has been subject to controversy (Marchant and Patel, 2013; Puertollano and Kiselyov, 2009) likely related to the special challenges associated with characterizing intracellular as opposed to plasma membrane-targeted channels.

Here, Grimm (2016) discusses the rapidly advancing pharmacology of TRPMLs, in particular the identification of TRPML agonists and antagonists (Chen et al., 2014; Grimm et al., 2010; Samie et al., 2013). The pharmacology of TPCs is relatively poorly characterised and limited to modifiers of voltage-gated Ca²⁺ and Na⁺ channels (Rahman et al., 2014; Sakurai et al., 2015). Nevertheless indirect inhibitors such as the antagonists of the Ca²⁺ mobilising messenger NAADP, a TPC activator, are proving useful (Davidson et al., 2015; Naylor et al., 2009).

As discussed throughout the reviews in this issue, chemical tools targeting TRPMLs and TPCs are providing new insights into the function and dysfunction of these channels in various neurodegenerative contexts.

TRPML1 AND NEURODEGENERATION

The role of TRPML1 in MLIV has been well reviewed and the reader is referred to recent articles (Ahuja et al., 2016; Bach et al., 2010; Grimm et al., 2012; Venkatachalam et al., 2015; Wang et al., 2014). Grimm covers work demonstrating correction of lysosomal storage in MLIV fibroblasts by synthetic TRPML agonists (Chen et al., 2014; Grimm, 2016). This is significant as it opens up

new therapeutic options for forms of the disease where TRPML1 activity is not completely lost. Notably, growing evidence suggests that TRPML1 function might also be compromised in disorders such as Niemann–Pick disease, type C (NPC) (Shen et al., 2012), a distinct lysosomal storage disorder, and Alzheimer's disease (Lee et al., 2015) amongst others. Here, reviews by Lloyd-Evans (2016) and Feng and Yang (2016) provide overviews of the relevant literature.

It was using various models of NPC that a clear link between lysosomal Ca²⁺ and lysosomal storage was uncovered (Lloyd-Evans et al., 2008). Lysosomal Ca²⁺ levels measured directly (using endocytosed Ca²⁺ indicators) or indirectly (through cytosolic Ca²⁺ signals in response to the lysosomotropic agent GPN) suggested that they were lower in NPC, and that lysosomal Ca²⁺ depletion was an early step in the pathogenesis. Although supported by independent studies (reviewed by Lloyd-Evans (2016)), more recent findings suggest that TRPML1 channels are inhibited by the accumulation of sphingomyelins in NPC rather than a reduction in stored Ca²⁺ (Shen et al., 2012). However, whether reductions in total Ca²⁺ were masked by secondary ER Ca²⁺ release (Kilpatrick et al., 2013) remains a formal possibility. Nevertheless, both studies concur that lysosomal Ca²⁺ signalling is inhibited in the disease (Lloyd-Evans et al., 2008; Shen et al., 2012). Importantly, boosting activity of endogenous TRPML1 with a synthetic TRPML agonist in NPC reversed lysosomal storage (Shen et al., 2012). Chemical activation of TRPML1 has also been reported to clear lysosomal amyloid β -peptides and sphingomyelin in cellular models of HIV dementia (Bae et al., 2014). However, in these cells TRPML channels appeared to be hyperactive. It is worth mentioning that TRPML1 activity in these studies (Bae et al., 2014; Shen et al., 2012) was measured using a genetically-encoded Ca²⁺ indicator fused to TRPML1 (Zhong et al., 2016b). Although elegant, the approach requires overexpression of TRPML1 which as shown recently triggers Ca²⁺ influx and ER Ca²⁺ release (Kilpatrick et al., 2016b). Such coupling might confound interpretation of the resulting signals.

Both TRPMLs and TPCs are regulated by the endo-lysosomal phosphoinositide, phosphatidylinositol-3,5-bisphosphate (PI(3,5)P₂) (Dong et al., 2010; Jha et al., 2014; Wang et al., 2012). Levels of this lipid are governed by PIKfyve and FIG4 (Dove et al., 2009). Mutations in the gene encoding FIG4 lower PI(3,5)P₂ levels and are associated with Charcot-Marie-Tooth peripheral neuropathy type 4J (CMT4J) (Chow et al., 2007) as well as a number of other disorders. In FIG4 knockout cells, lysosomal Ca²⁺ levels measured using Calcium Orange were elevated (Zou et al., 2015). As in NPC and HIV dementia models, chemical activation of TRPMLs normalised lysosomal dysfunction. These findings again suggest compromised TRPML activity, presumably due to PI(3,5)P₂ deficiency that results

in Ca²⁺ accumulation within lysosomes. Elevated lysosomal Ca²⁺ levels upon FIG4 depletion are reminiscent of the findings in *Drosophila* upon knockout of its single mucolipin homologue (Wong et al., 2012) and in some TRPML1-deficient mammalian cells (Cao et al., 2015b) but not others (Soyombo et al., 2006).

Finally, recent work by Lee et al. show that lysosomal Ca²⁺ levels are reduced in cells lacking the Alzheimer disease-linked gene, Presenilin 1 (*PSEN1*) (Lee et al., 2015). These findings are consistent with earlier findings in *PSEN1* and *PSEN2* double knockout cells (Coen et al., 2012). Interestingly, endogenous Ca²⁺ responses to a synthetic TRPML agonist were paradoxically enhanced upon *PSEN1* knockout, pointing to a model whereby the hyperactivation of TRPML1 lowers steady state lysosomal Ca²⁺ levels (Lee et al., 2015). In accord, reduced lysosomal Ca²⁺ and the associated elevation in cytosolic Ca²⁺ were reversed by knockdown of TRPML1. Interestingly, treatment of *PSEN1*-deficient cells with an NAADP antagonist was also effective in resetting Ca²⁺ homeostasis but knockdown of TPC2 was not. These data suggest complex interplay between TRPML and NAADP signalling possibly involving TPC1. Normalising Ca²⁺ levels however failed to reverse proteolytic and autophagic defects in *PSEN1*-deficient cells. Rather the associated changes in lysosomal pH upon *PSEN* knockout (albeit disputed) appeared to be more functionally relevant (Lee et al., 2015).

In sum, TRPML1 has been implicated in a number of neurodegenerative diseases with evidence for both a gain and loss of function in activity associated with complex effects on lysosomal Ca²⁺ content.

TPC2 AND NEURODEGENERATION

Like, TRPML1, TPC2 has also been linked to neurodegeneration. Reviews in this issue by both Hilfiker and colleagues (Rivero-Rios et al., 2016), and Kilpatrick (2016) discuss defective lysosomal Ca²⁺ signalling in Parkinson disease. Initial overexpression studies of the Parkinson disease-linked protein LRRK2 identified autophagic defects (Gomez-Suaga et al., 2012), adding to what is now a body of literature implicating endo-lysosomal dysfunction in the disease (Abeliovich and Gitler, 2016). Importantly, these defects were recapitulated upon NAADP treatment and reversed by chemically antagonising NAADP action or by overexpressing a dominant-negative TPC2 construct (Gomez-Suaga et al., 2012).

Subsequent work by Hockey et al. identified endo-lysosomal morphology defects in Parkinson disease patient fibroblasts carrying the G2019S mutation in LRRK2 (Hockey et al., 2015). Again, these defects were reversed by NAADP antagonism including a novel analogue better suited for *in vivo* studies. Chemical or molecular inhibition of TPCs, local Ca²⁺ fluxes, PI(3,5)P₂ signalling, and the TPC-interactor Rab7 (Lin-Moshier et al., 2014) all

reversed endo-lysosomal morphology defects, further highlighting this axis as a potential therapeutic target (Hockey et al., 2015). Like in *PSEN1*-deficient cells, these data point to a gain of function in lysosomal Ca²⁺ signalling. In accord, NAADP-evoked Ca²⁺ signals were enhanced upon mutation of LRRK2. Steady state lysosomal Ca²⁺ levels were not measured in *LRRK2*-linked Parkinson disease. However, as further discussed by Kilpatrick (2016), lysosomal Ca²⁺ levels were reduced in *GBA1*-linked Parkinson disease (Kilpatrick et al., 2016a). This form of the disease is due to mutations in glucocerebrosidase, a lysosomal enzyme, and is highly relevant because recessive mutations in *GBA1* cause Gaucher disease, another lysosomal storage disorder.

Rare lysosomal storage disorders and more common neurodegenerative disease thus seem to be intimately linked through defects in lysosomal Ca²⁺.

A ROLE FOR OTHER LYOSOMAL CHANNELS IN NEURODEGENERATION?

Whereas TRPMLs and TPCs localise predominantly to the endo-lysosomal system, other Ca²⁺-permeable channels traditionally thought of as plasma membrane proteins are also found within lysosomes. These include TRPM2 (Lange et al., 2009), P2X4 (Qureshi et al., 2007) and more recently the voltage-gated Ca²⁺ channel, Cav2.1 (Tian et al., 2015) and TRPA1 (Shang et al., 2016). This raises the possibility that these channels might also (de) regulate lysosomal Ca²⁺ signalling. Indeed, autophagic defects in neurons from the *leaner* mouse have been ascribed to lysosomal Cav2.1 (Tian et al., 2015) which might link defective lysosomal Ca²⁺ signalling to neurodegenerative diseases associated with Cav2.1 mutation such as episodic ataxia 2. By the same logic, perhaps lysosomal P2X4 and TRPA1 contribute to neuropathic pain which is often associated with neurodegeneration.

Although not a Ca²⁺ channel, the big-conductance Ca²⁺-activated K⁺ (BK) channel, Slo1 also localises to lysosomes, interacts with TRPML1 and is thought to provide a counter current to sustain Ca²⁺ release (Cao et al., 2015b). Notably, overexpression or chemical activation of Slo1 reverses storage phenotypes in patient fibroblasts from several lysosomal storage disorders including NPC and MLIV (Cao et al., 2015b; Zhong et al., 2016a).

The number of lysosomal ion channels potentially relevant for neurodegeneration is steadily growing.

LYSOSOMAL Ca²⁺-PERMEABLE CHANNELS AND ENDO-LYSOSOMAL TRAFFICKING

Ca²⁺-regulates endo-lysosome fusion and lysosome reformation necessary for endo-lysosomal trafficking (Pryor et al., 2000). Thus, the identification of an endo-lysosomal

Ca²⁺ permeable channel (TRPML1) immediately suggested a mechanism to explain aberrant lysosome morphology and the mis-trafficking of lipids characteristic upon loss of channel function (in MLIV) (Pryor et al., 2006). However, pinpointing the exact subcellular 'lesion' is challenging due to the difficulties in assaying these dynamic processes in live cells and the interconnected and heterogeneous nature of the endocytic system.

In the case of TPC2, it is clear that gain-of function, be it pathological (manifest in Parkinson disease) (Hockey et al., 2015) or experimental (upon TPC2 overexpression) (Lin-Moshier et al., 2014), enlarges lysosomes. This points to a fusogenic role for TPC2 within the endo-lysosomal system, as discussed in the review by Hilficker (Rivero-Rios et al., 2016). Indeed, TPCs associate with the fusogenic machinery (Grimm et al., 2014; Lin-Moshier et al., 2014; Marchant and Patel, 2015). Similar roles for P2X4 in endo-lysosome fusion (Cao et al., 2015a) and Cav2.1 in endo-lysosome/autophagosome fusion (Tian et al., 2015) have also been advanced. In the case of TRPML1 however, it is loss of function that consistently results in lysosome enlargement. Might this result due to a block in fission. In accord, fission is altered in FIG4-deficient cells in a TRPML-dependent manner (Zou et al., 2015). But potential fusogenic roles for TRPML1 in the context of endo-lysosome/amphisome fusion in *Drosophila* (Wong et al., 2012) and lysosomal exocytosis in mammalian cells (Samie et al., 2013) should not be ignored.

In sum, lysosomal channel dysfunction is associated with endo-lysosomal trafficking defects but the mechanistic details are still hazy.

SCOPE

Growing evidence links dysregulated lysosomal Ca²⁺ signalling to neurodegeneration. Currently available small molecule activators and inhibitors, together with molecular manipulations, have been used with promising effect to reverse cellular phenotypes and identify the relevant target channels. But mechanistically, potentiation or inhibition of target channels does not always intuitively correlate with steady-state levels of lysosomal Ca²⁺. This underscores the need for rigorous analyses of lysosomal Ca²⁺ signals and better methods to do so. Indeed, flux of other ions such as Fe²⁺ through TRPML1 (Dong et al., 2008) and likely TPCs too (Fernandez et al., 2016) might also be functionally relevant. Whilst, there is no doubt that channel dysfunction is manifest in vesicular trafficking defects, further work is required to more precisely delineate the affected processes. Finally, considering potential roles for lysosomal ion channels in regulating non-vesicular traffic may also be of merit given physical contact of endo-lysosomes with other organelles (Kilpatrick et al., 2013) and the regulation of such contact by stored Ca²⁺ (Kilpatrick et al., 2017). These considerations will no doubt advance the

ultimate aim of developing novel mechanism-based therapeutics for tackling neurodegeneration in our ever-aging population.

Acknowledgments: I thank Xianping Dong, Christian Grimm, Bethan Kilpatrick and Christopher Penny for comments on the manuscript. Work in my laboratory is funded by the BBSRC and Parkinson's UK.

REFERENCES

- Abeliovich, A. and Gitler, A. D. (2016). Defects in trafficking bridge Parkinson's disease pathology and genetics. *Nature* 539, 207–216.
- Ahuja, M., Park, S., Shin, D. M., and Muallem, S. (2016). TRPML1 as lysosomal fusion guard. *Channels (Austin)* 10, 261–263.
- Bach, G., Zeevi, D. A., Frumkin, A., and Kogot-Levin, A. (2010). Mucopolipidosis type IV and the mucopolipins. *Biochem. Soc. Trans.* 38, 1432–1435.
- Bae, M., Patel, N., Xu, H., Lee, M., Tominaga-Yamanaka, K., Nath, A., Geiger, J., Gorospe, M., Mattson, M. P., and Haughey, N. J. (2014). Activation of TRPML1 clears intraneuronal Abeta in preclinical models of HIV infection. *J. Neurosci.* 34, 11485–11503.
- Bargal, R., Avidan, N., Ben-Asher, E., Olender, Z., Zeigler, M., Frumkin, A., Raas-Rothschild, A., Glusman, G., Lancet, D., and Bach, G. (2000). Identification of the gene causing mucopolipidosis type IV. *Nat. Genet.* 26, 118–123.
- Berridge, M. J. (2002). The endoplasmic reticulum: A multifunctional signaling organelle. *Cell Calcium* 32, 235–249.
- Brailoiu, E., Rahman, T., Churamani, D., Prole, D. L., Brailoiu, G. C., Hooper, R., Taylor, C. W., and Patel, S. (2010). An NAADP-gated two-pore channel targeted to the plasma membrane uncouples triggering from amplifying Ca²⁺ signals. *J. Biol. Chem.* 285, 38511–38516.
- Cao, Q., Zhong, X. Z., Zou, Y., Murrell-Lagnado, R., Zhu, M. X., and Dong, X. P. (2015a). Calcium release through P2X4 activates calmodulin to promote endolysosomal membrane fusion. *J. Cell Biol.* 209, 879–894.
- Cao, Q., Zhong, X. Z., Zou, Y., Zhang, Z., Toro, L., and Dong, X. P. (2015b). BK channels alleviate lysosomal storage diseases by providing positive feedback regulation of lysosomal Ca²⁺ release. *Dev. Cell* 33, 427–441.
- Chen, C. C., Keller, M., Hess, M., Schiffmann, R., Urban, N., Wolfgardt, A., Schaefer, M., Bracher, F., Biel, M., Wahl-Schott, C., and Grimm, C. (2014). A small molecule restores function to TRPML1 mutant isoforms responsible for mucopolipidosis type IV. *Nat. Commun.* 5, 4681.
- Chow, C. Y., Zhang, Y., Dowling, J. J., Jin, N., Adamska, M., Shiga, K., Szigeti, K., Shy, M. E., Li, J., Zhang, X., Lupski, J. R., Weisman, L. S., and Meisler, M. H. (2007). Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. *Nature* 448, 68–72.
- Christensen, K. A., Myers, J. T., and Swanson, J. A. (2002). pH-dependent regulation of lysosomal calcium in macrophages. *J. Cell Sci.* 115, 599–607.
- Coen, K., Flannagan, R. S., Baron, S., Carraro-Lacroix, L. R., Wang, D., Vermeire, W., Michiels, C., Munck, S., Baert, V., Sugita, S., Wuytack, F., Hiesinger, P. R., Grinstein, S., and Annaert, W. (2012). Lysosomal calcium homeostasis defects, not proton pump defects, cause endolysosomal dysfunction in PSEN-deficient cells. *J. Cell Biol.* 198, 23–25.
- Davidson, S. M., Foote, K., Kunuthur, S., Gosain, R., Tan, N., Tyser, R., Zhao, Y. J., Graeff, R., Ganesan, A., Duchon, M. R., Patel, S., and Yellon, D. M. (2015). Inhibition of NAADP signalling on reperfusion protects the heart by preventing lethal calcium oscillations via two-pore channel 1 and opening of the mitochondrial permeability transition pore. *Cardiovasc Res.* 108, 357–366.

- Dong, X. P., Cheng, X., Mills, E., Dellling, M., Wang, F., Kurz, T., and Xu, H. (2008). The type IV mucopolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. *Nature* 455, 992–996.
- Dong, X. P., Shen, D., Wang, X., Dawson, T., Li, X., Zhang, Q., Cheng, X., Zhang, Y., Weisman, L. S., Dellling, M., and Xu, H. (2010). PI(3,5)P₂ controls membrane traffic by direct activation of mucolipin Ca²⁺ release channels in the endolysosome. *Nat. Commun.* 1, 38.
- Dove, S. K., Dong, K., Kobayashi, T., Williams, F. K., and Michell, R. H. (2009). Phosphatidylinositol 3,5-bisphosphate and Fab1p/PIKfyve underPPIn endo-lysosome function. *Biochem. J.* 419, 1–13.
- Feng, X. and Yang, J. (2016). Lysosomal calcium in neurodegeneration. *Messenger* 5, 56–65.
- Fernandez, B., Fdez, E., Gomez-Suaga, P., Gil, F., Molina-Villalba, I., Ferrer, I., Patel, S., Churchill, G. C., and Hilfiker, S. (2016). Iron overload causes endolysosomal deficits modulated by NAADP-regulated 2-pore channels and RAB7A. *Autophagy* 12, 1487–1506.
- Galione, A., Evans, A. M., Ma, J., Parrington, J., Arredouani, A., Cheng, X., and Zhu, M. X. (2009). The acid test: The discovery of two-pore channels (TPCs) as NAADP-gated endolysosomal Ca(2+) release channels. *Pflugers Arch.* 458, 869–876.
- Gomez-Suaga, P., Luzon-Toro, B., Churamani, D., Zhang, L., Bloor-Young, D., Patel, S., Woodman, P. G., Churchill, G. C., and Hilfiker, S. (2012). Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. *Hum. Mol. Genet.* 21, 511–525.
- Grimm, C. (2016). Endolysosomal cation channels as therapeutic targets—Pharmacology of TRPML channels. *Messenger* 5, 30–36.
- Grimm, C., Chen, C. C., Wahl-Schott, C., and Biel, M. (2017). Two-pore channels: Catalysts of endolysosomal transport and function. *Front Pharmacol.* 8, 45.
- Grimm, C., Hassan, S., Wahl-Schott, C., and Biel, M. (2012). Role of TRPML and two-pore channels in endolysosomal cation homeostasis. *J. Pharmacol. Exp. Ther.* 342, 236–244.
- Grimm, C., Holdt, L. M., Chen, C. C., Hassan, S., Müller, C., Jors, S., Cuny, H., Kissing, S., Schroder, B., Butz, E., Northoff, B., Castonguay, J., Lubber, C. A., Moser, M., Spahn, S., Lullmann-Rauch, R., Fendel, C., Klugbauer, N., Griesbeck, O., Haas, A., Mann, M., Bracher, F., Teupser, D., Saftig, P., Biel, M., and Wahl-Schott, C. (2014). High susceptibility to fatty liver disease in two-pore channel 2-deficient mice. *Nat. Commun.* 5, 4699.
- Grimm, C., Jors, S., Saldanha, S. A., Obukhov, A. G., Pan, B., Oshima, K., Cuajungco, M. P., Chase, P., Hodder, P., and Heller, S. (2010). Small molecule activators of TRPML3. *Chem. Biol.* 17, 135–148.
- Hockey, L. N., Kilpatrick, B. S., Eden, E. R., Lin-Moshier, Y., Brailoiu, G. C., Brailoiu, E., Futter, C., Schapira, A. H., Marchant, J. S., and Patel, S. (2015). Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition. *J. Cell Sci.* 128, 232–238.
- Jha, A., Ahuja, M., Patel, S., Brailoiu, E., and Muallem, S. (2014). Convergent regulation of the lysosomal two-pore channel-2 by Mg²⁺, NAADP, PI(3,5)P₂ and multiple protein kinases. *EMBO J.* 33, 501–511.
- Kilpatrick, B. S. (2016). Connecting Ca²⁺ and lysosomes to Parkinson disease. *Messenger* 5, 75–85.
- Kilpatrick, B. S., Eden, E. R., Hockey, L. N., Yates, E., Futter, C. E., and Patel, S. (2017). An endosomal NAADP-sensitive two-pore Ca²⁺ channel regulates ER-endosome membrane contact sites to control growth factor signaling. *Cell Rep.* 18, 1636–1645.
- Kilpatrick, B. S., Eden, E. R., Schapira, A. H., Futter, C. E., and Patel, S. (2013). Direct mobilisation of lysosomal Ca²⁺ triggers complex Ca²⁺ signals. *J. Cell Sci.* 126, 60–66.
- Kilpatrick, B. S., Magalhaes, J., Beavan, M. S., McNeill, A., Gegg, M. E., Cleeter, M. W., Bloor-Young, D., Churchill, G. C., Duchen, M. R., Schapira, A. H., and Patel, S. (2016a). Endoplasmic reticulum and lysosomal Ca²⁺ stores are remodelled in GBA1-linked parkinson disease patient fibroblasts. *Cell Calcium* 59, 12–20.
- Kilpatrick, B. S., Yates, E., Grimm, C., Schapira, A. H., and Patel, S. (2016b). Endo-lysosomal TRP mucolipin-1 channels trigger global ER Ca²⁺ release and Ca²⁺ influx. *J. Cell Sci.* 129, 3859–3867.
- Lange, I., Yamamoto, S., Partida-Sanchez, S., Mori, Y., Fleig, A., and Penner, R. (2009). TRPM2 functions as a lysosomal Ca²⁺-release channel in beta cells. *Sci. Signal* 2, ra23.
- LaPlante, J. M., Falardeau, J., Sun, M., Kanazirska, M., Brown, E. M., Slaugenhaupt, S. A., and Vassilev, P. M. (2002). Identification and characterization of the single channel function of human mucolipin-1 implicated in mucopolipidosis type IV, a disorder affecting the lysosomal pathway. *FEBS Lett.* 532, 183–187.
- Lee, J. H., McBrayer, M. K., Wolfe, D. M., Haslett, L. J., Kumar, A., Sato, Y., Lie, P. P., Mohan, P., Coffey, E. E., Kompella, U., Mitchell, C. H., Lloyd-Evans, E., and Nixon, R. A. (2015). Presenilin 1 maintains lysosomal Ca(2+) homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. *Cell Rep.* 12, 1430–1444.
- Lin-Moshier, Y., Keebler, M. V., Hooper, R., Boulware, M. J., Liu, X., Churamani, D., Abood, M. E., Walseth, T. F., Brailoiu, E., Patel, S., and Marchant, J. S. (2014). The two-pore channel (TPC) interactome unmasks isoform-specific roles for TPCs in endolysosomal morphology and cell pigmentation. *Proc. Natl. Acad. Sci.* 111, 13087–13092.
- Lloyd-Evans, E. (2016). Acidic Ca²⁺ stores in neurodegeneration. *Messenger* 5, 37–55.
- Lloyd-Evans, E., Morgan, A. J., He, X., Smith, D. A., Elliot-Smith, E., Sillence, D. J., Churchill, G. C., Schuchman, E. H., Galione, A., and Platt, F. M. (2008). Niemann-pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. *Nat. Med.* 14, 1247–1255.
- Lopez-Sanjurjo, C. I., Tovey, S. C., Prole, D. L., and Taylor, C. W. (2013). Lysosomes shape Ins(1,4,5)P₃-evoked Ca²⁺ signals by selectively sequestering Ca²⁺ released from the endoplasmic reticulum. *J. Cell Sci.* 126, 289–300.
- Marchant, J. S. and Patel, S. (2013). Questioning regulation of two-pore channels by NAADP. *Messenger* 2, 113–119.
- Marchant, J. S. and Patel, S. (2015). Two-pore channels at the intersection of endolysosomal membrane traffic. *Biochemical Society Transactions.* 43, 434–441.
- Melchionda, M., Pittman, J. K., Mayor, R., and Patel, S. (2016). Ca²⁺/H⁺ exchange by acidic organelles regulates cell migration *in vivo*. *J. Cell Biol.* 212, 803–813.
- Morgan, A. J., Platt, F. M., Lloyd-Evans, E., and Galione, A. (2011). Molecular mechanisms of endolysosomal Ca²⁺ signalling in health and disease. *Biochem. J.* 439, 349–374.
- Naylor, E., Arredouani, A., Vasudevan, S. R., Lewis, A. M., Parkesh, R., Mizote, A., Rosen, D., Thomas, J. M., Izumi, M., Ganesan, A., Galione, A., and Churchill, G. C. (2009). Identification of a chemical probe for NAADP by virtual screening. *Nat. Chem. Biol.* 5, 220–226.
- Patel, S. (2015). Function and dysfunction of two-pore channels. *Sci. Signal.* 8, re7.
- Patel, S. and Cai, X. (2015). Evolution of acid Ca²⁺ stores and their resident Ca²⁺-permeable channels. *Cell Calcium* 57, 222–230.
- Patel, S. and Docampo, R. (2010). Acidic calcium stores open for business: Expanding the potential for intracellular Ca²⁺ signaling. *Trends Cell Biol.* 20, 277–286.
- Patel, S. and Muallem, S. (2011). Acidic Ca²⁺ stores come to the fore. *Cell Calcium* 50, 109–112.

- Pryor, P. R., Mullock, B. M., Bright, N. A., Gray, S. R., and Luzio, J. P. (2000). The role of intraorganellar Ca²⁺ in late endosome-lysosome heterotypic fusion and in the reformation of lysosomes from hybrid organelles. *J. Cell Biol.* 149, 1053–1062.
- Pryor, P. R., Reimann, F., Gribble, F. M., and Luzio, J. P. (2006). Muclolipin-1 is a lysosomal membrane protein required for intracellular lactosylceramide traffic. *Traffic* 7, 1388–1398.
- Puertollano, R. and Kiselyov, K. (2009). TRPMLs: In sickness and in health. *Am J. Physiol. Renal. Physiol.* 296, F1245–F1254.
- Qureshi, O. S., Paramasivam, A., Yu, J. C., and Murrell-Lagnado, R. D. (2007). Regulation of P2X4 receptors by lysosomal targeting, glycan protection and exocytosis. *J. Cell Sci.* 120, 3838–3849.
- Rahman, T., Cai, X., Brailoiu, G. C., Abood, M. E., Brailoiu, E., and Patel, S. (2014). Two-pore channels provide insight into the evolution of voltage-gated Ca²⁺ and Na⁺ channels. *Sci. Signal* 7, ra109.
- Rivero-Rios, P., Fernandez, B., Madero-Perez, J., Romo Lazano, M., and Hilfiker, S. (2016). Two-pore channels and Parkinson's disease: Where's the link? *Messenger* 5, 66–74.
- Sakurai, Y., Kolokolstov, A. A., Chen, C. C., Tidwell, M. W., Bauta, W. E., Klugbauer, N., Grimm, C., Wahl-Schott, C., Biel, M., and Davey, R. A. (2015). Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. *Science* 347, 6225.
- Samie, M., Wang, X., Zhang, X., Goschka, A., Li, X., Cheng, X., Gregg, E., Azar, M., Zhuo, Y., Garrity, A. G., Gao, Q., Slaugenhaupt, S., Pickel, J., Zolov, S. N., Weisman, L. S., Lenk, G. M., Titus, S., Bryant-Genevier, M., Southall, N., Juan, M., Ferrer, M., and Xu, H. (2013). A TRP channel in the lysosome regulates large particle phagocytosis via focal exocytosis. *Dev. Cell* 26, 511–524.
- Schieder, M., Rotzer, K., Bruggemann, A., Biel, M., and Wahl-Schott, C. A. (2010). Characterization of two-pore channel 2 (TPCN2)-mediated Ca²⁺ currents in isolated lysosomes. *J. Biol. Chem.* 285, 21219–21222.
- Shang, S., Zhu, F., Liu, B., Chai, Z., Wu, Q., Hu, M., Wang, Y., Huang, R., Zhang, X., Wu, X., Sun, L., Wang, Y., Wang, L., Xu, H., Teng, S., Liu, B., Zheng, L., Zhang, C., Zhang, F., Feng, X., Zhu, D., Wang, C., Liu, T., Zhu, M. X., and Zhou, Z. (2016). Intracellular TRPA1 mediates Ca²⁺ release from lysosomes in dorsal root ganglion neurons. *J. Cell Biol.* 215, 369–381.
- Shen, D., Wang, X., Li, X., Zhang, X., Yao, Z., Dibble, S., Dong, X. P., Yu, T., Lieberman, A. P., Showalter, H. D., and Xu, H. (2012). Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release. *Nat. Commun.* 3, 731.
- Soyombo, A. A., Tjon-Kon-Sang, S., Rbaibi, Y., Bashllari, E., Bisceglia, J., Muallem, S., and Kiselyov, K. (2006). TRP-ML1 regulates lysosomal pH and acidic lysosomal lipid hydrolytic activity. *J. Biol. Chem.* 281, 7294–7301.
- Tian, X., Gala, U., Zhang, Y., Shang, W., Nagarkar, J. S., Di, R. A., Jaiswal, M., Yamamoto, S., Sandoval, H., Duraine, L., Sardiello, M., Sillitoe, R. V., Venkatachalam, K., Fan, H., Bellen, H. J., and Tong, C. (2015). A voltage-gated calcium channel regulates lysosomal fusion with endosomes and autophagosomes and is required for neuronal homeostasis. *PLoS Biol.* 13, e1002103.
- Venkatachalam, K., Wong, C. O., and Zhu, M. X. (2015). The role of TRPMLs in endolysosomal trafficking and function. *Cell Calcium* 58, 48–56.
- Vergarajauregui, S. and Puertollano, R. (2006). Two di-leucine motifs regulate trafficking of muclolipin-1 to lysosomes. *Traffic* 7, 337–353.
- Wang, W., Zhang, X., Gao, Q., and Xu, H. (2014). TRPML1: An ion channel in the lysosome. *Handb. Exp. Pharmacol.* 222, 631–645.
- Wang, X., Zhang, X., Dong, X. P., Samie, M., Li, X., Cheng, X., Goschka, A., Shen, D., Zhou, Y., Harlow, J., Zhu, M. X., Clapham, D. E., Ren, D., and Xu, H. (2012). TPC proteins are phosphoinositide-activated sodium-selective ion channels in endosomes and lysosomes. *Cell* 151, 372–383.
- Wong, C. O., Li, R., Montell, C., and Venkatachalam, K. (2012). Drosophila TRPML is required for TORC1 activation. *Curr. Biol.* 22, 1616–1621.
- Xu, H. and Ren, D. (2015). Lysosomal physiology. *Annu. Rev. Physiol.* 77, 57–80.
- Yamasaki, M., Masgrau, R., Morgan, A. J., Churchill, G. C., Patel, S., Ashcroft, S. J. H., and Galione, A. (2004). Organelle selection determines agonist-specific Ca²⁺ signals in pancreatic acinar and beta cells. *J. Biol. Chem.* 279, 7234–7240.
- Zhong, X. Z., Sun, X., Cao, Q., Dong, G., Schiffmann, R., and Dong, X. P. (2016a). BK channel agonist represents a potential therapeutic approach for lysosomal storage diseases. *Sci. Rep.* 6, 33684.
- Zhong, X. Z., Yang, Y., Sun, X., and Dong, X. P. (2016b). Methods for monitoring Ca²⁺ and ion channels in the lysosome. *Cell Calcium*. <https://www.ncbi.nlm.nih.gov/pubmed/27986285>, ePub ahead of print.
- Zou, J., Hu, B., Arpag, S., Yan, Q., Hamilton, A., Zeng, Y. S., Vanoye, C. G., and Li, J. (2015). Reactivation of lysosomal Ca²⁺ efflux rescues abnormal lysosomal storage in FIG4-deficient cells. *J. Neurosci.* 35, 6801–6812.

Received: 26 February 2017. Accepted: 28 February 2017.